NEW YORK (GenomeWeb) – Editas Medicine will offer 5.9 million shares of common stock in its planned initial public offering, at a price of $16 per share, according to a document filed today with the US Securities and Exchange Commission.

The Cambridge, Massachusetts-based firm said it expects to raise $94.4 million — $87.8 million in proceeds after discounts and commissions to the underwriters.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.